Tyme Technologies (TYME) is moving closer to a transformative point in the company’s history. Tyme is now working on their enrollment of two pancreatic cancer pivotal trials for SM-88. If successful, these programs will bring tremendous value to the company and their shareholders. So far, the company has reported encouraging efficacy and safety data that hints towards success where many other companies have failed. Recently, the company secured a strategic partnership with Eagle Pharmaceuticals (EGRX) that supplied the company with a healthy upfront payment and additional milestones. This allows the company